Revisor Wealth Management LLC Sells 2,115 Shares of Johnson & Johnson (NYSE:JNJ)

Revisor Wealth Management LLC cut its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 45.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,579 shares of the company's stock after selling 2,115 shares during the quarter. Revisor Wealth Management LLC's holdings in Johnson & Johnson were worth $375,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of JNJ. Tallon Kerry Patrick bought a new stake in Johnson & Johnson in the 4th quarter valued at about $290,000. Capital & Planning LLC grew its stake in Johnson & Johnson by 13.6% in the fourth quarter. Capital & Planning LLC now owns 1,528 shares of the company's stock valued at $221,000 after acquiring an additional 183 shares during the period. Mitchell & Pahl Private Wealth LLC increased its holdings in shares of Johnson & Johnson by 4.2% during the fourth quarter. Mitchell & Pahl Private Wealth LLC now owns 18,174 shares of the company's stock valued at $2,628,000 after acquiring an additional 739 shares in the last quarter. Sugar Maple Asset Management LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $60,000. Finally, Hamlin Capital Management LLC lifted its holdings in shares of Johnson & Johnson by 9.6% in the 4th quarter. Hamlin Capital Management LLC now owns 1,076,740 shares of the company's stock worth $155,718,000 after purchasing an additional 94,147 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Insiders Place Their Bets

In other news, VP Robert J. Decker sold 6,999 shares of the firm's stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Performance

JNJ stock opened at $153.12 on Friday. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The firm has a market cap of $368.41 billion, a PE ratio of 23.02, a P/E/G ratio of 2.56 and a beta of 0.42. The business has a 50 day moving average of $155.24 and a 200-day moving average of $153.72. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. As a group, sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 3.40%. The ex-dividend date of this dividend is Tuesday, May 27th. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio (DPR) is 57.84%.

Analyst Ratings Changes

Several research firms recently issued reports on JNJ. Bank of America reduced their price target on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research report on Thursday, April 10th. Argus upgraded shares of Johnson & Johnson to a "strong-buy" rating in a report on Friday, January 24th. Barclays decreased their target price on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. Guggenheim reaffirmed a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Finally, Morgan Stanley lifted their price target on Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a research note on Wednesday, April 16th. Eleven investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.